Tag: Nasdaq:ARGX

December 19, 2018

Biotech Outlook 2019: Will the Pressure Continue?

With 2018 coming to an end, what's the biotech outlook? Next year will bring new investing opportunities for those in...
October 3, 2018

VIDEO — Life Science Update September 2018

With September officially behind us, the Investing News Network is taking a look back at some of the biggest news...
September 17, 2018

Argenx Releases Positive Trial Results

On Monday, Argenx released positive clinical data from a proof-of-concept trial for its rare disease drug, efgartigimoid (ARGX-113).
September 17, 2018

argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

argenx (Nasdaq:ARGX) announced positive topline results from its Phase 2 proof-of-concept clinical trial of efgartigimod (ARGX-113) in adult primary immune...